Skip to main content
SpringerLink
Log in

PD-L1 testing increases cost effectiveness

  • Clinical study
  • Published:
PharmacoEconomics & Outcomes News

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Notes

  1. tumour programmed death ligand one

  2. 2016 US dollars

Reference

  • Aguiar PN Jr, et al. The effect of PD-L1 testing on the cost-effectiveness and economic impact of immune checkpoint inhibitors for the second-line treatment of NSCLC. Annals of Oncology 28: 2256-2263, No. 9, 1 Sep 2017. Available from: URL: http://doi.org/10.1093/annonc/mdx305

    PubMed  Google Scholar 

Download references

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

PD-L1 testing increases cost effectiveness. PharmacoEcon Outcomes News 788, 24 (2017). https://doi.org/10.1007/s40274-017-4392-y

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s40274-017-4392-y

Search

Navigation